You are here: Industry Insights > AD

News List

Patients gain early access to Pfizer's atopic dermatitis drug pharmatimes
February 04, 2021
People living in the UK with severe atopic dermatitis are to be given early access to Pfizer's abrocitinib following a green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
Biohaven Provides Update on Phase 2/3 Trial, Alzheimer's Program americanpharmaceuticalreview
January 20, 2021
Biohaven Pharmaceutical has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD).
Antipsychotic Initiation Ups Risk for Head Injury, TBI in Alzheimer Disease drugs
January 20, 2020
Individuals with Alzheimer disease (AD) initiating antipsychotics have an increased risk for head injuries and traumatic brain injury (TBI), according to a study published online January in the Journal of the American Geriatrics Society.
Connect Biopharma Reports Positive Data from Atopic Dermatitis Study americanpharmaceuticalreview
January 09, 2020
Connect Biopharma announced positive topline data from the Phase 1b study of its novel IL-4Rα antibody, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD).
Study Shows Link Between Atopic Dermatitis and Vitiligo drugs
January 02, 2020
Atopic dermatitis (AD) is associated with vitiligo, according to a review and meta-analysis published online December in the Journal of Cosmetic Dermatology.
2007 to 2014 Saw Decrease in U.S. Incidence of Alzheimer Disease drugs
December 19, 2019
From 2007 to 2014, there was a decrease in the diagnosed incidence of Alzheimer disease (AD), according to a study published online in the Journal of the American Geriatrics Society.
Novel PET Staging System May Help Monitor Alzheimer Disease drugs
July 19, 2019
A staging system of β-amyloid (Aβ) accumulation may be useful for monitoring patients throughout the course of Alzheimer disease (AD)...
Eczema-Related School Absences Higher Among Blacks, Hispanics drugs
May 30, 2019
Eczema-Related School Absences Higher Among Blacks, Hispanics.
Lilly Announces Top-Line Phase 3 Results for Baricitinib Trial americanpharmaceuticalreview
February 19, 2019
Eli Lilly and Company and Incyte announced baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with ....
High Levels of Activity, Motor Ability Linked to Better Cognition drugs
January 17, 2019
In older adults, higher levels of total daily activity and better motor abilities are associated with better cognition, according to a study published online Jan. 16 in Neurology.....

Previous page 1 2 3 Next page